文献速递皮肤肿瘤

心肺移植人群中黑色素瘤的发病率与表现分析

Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population.
PubMed 文献 · JAMA Dermatol · 2018-01-01

这项单中心回顾性队列研究纳入2001至2016年接受心肺移植的1154例患者,中位随访4.3年,5例(0.4%)发生活检证实的黑色素瘤,中位诊断时间为移植后2.5年,4例为I期、1例为IV期;作者认为心肺移植人群黑色素瘤发病率与其他实体器官移植受者相似,但研究规模小,需进一步研究。

要点

  • 1154例心肺移植患者中5例(0.4%)发生活检证实的黑色素瘤。
  • 黑色素瘤中位诊断时间为移植后2.5年,中位年龄64.5岁。
  • 4例(80%)为I期,1例(20%)为IV期;2例死亡,其中1例死于转移性黑色素瘤。

核心结论

  • 心肺移植人群黑色素瘤发病率与其他实体器官移植受者相似,移植至黑色素瘤诊断的中位时间为2.5年。
  • 研究规模小,无法得出深远结论,需进一步研究以更好地理解心肺移植人群黑色素瘤发生的发病率、时机和临床后果。

研究设计与样本

  • 单中心学术三级转诊中心的回顾性队列研究,纳入2001至2016年在杜克大学医院接受心肺移植的1164例患者。
  • 排除10例有黑色素瘤病史者,最终分析1154例,中位随访4.3年;暴露因素包括他克莫司、泼尼松和吗替麦考酚酯。

主要发现

  • 1154例心肺移植患者中5例(0.4%)发生活检证实的黑色素瘤,中位随访4.3年,中位年龄64.5岁(范围31.0-74.0岁)。
  • 1154例中923例(80%)为男性,平均(SD)年龄范围63.8岁(27.2-68.2岁)。
  • 4例(80%)为I期,1例(20%)为IV期;移植后至诊断的中位时间为2.5年(范围0.1-5.3年)。
  • 杜克大学肾移植人群移植后至诊断的中位时间为6.2年(范围0.9-8.7年),中位随访6.6年。
  • 2例患者移植后死亡,1例死于移植并发症,1例死于转移性黑色素瘤。

临床怎么用

  • 作者认为心肺移植人群黑色素瘤发病率与其他实体器官移植受者相似,移植至诊断的中位时间为2.5年。
  • 作者指出研究规模小,无法得出深远结论,需进一步研究以更好地理解心肺移植人群黑色素瘤发生的发病率、时机和临床后果。

局限性

  • 研究规模小,无法得出深远结论。
  • 需进一步研究以更好地理解心肺移植人群黑色素瘤发生的发病率、时机和临床后果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The immunosuppression vital to maintaining transplanted organs comes with an increased incidence of cutaneous neoplasms. Understanding the genesis of malignant melanoma (MM) in transplant subpopulations is necessary for adequate disease surveillance. OBJECTIVE: To determine the incidence and timing of presentation of MM in the cardiothoracic (heart and/or lung) transplant (CTT) population. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of 1164 patients who underwent a CTT from 2001 through 2016 with a median follow-up time of 4.3 years. The study was performed at a single academic, tertiary referral center. The retrospective database was used to identify 1164 patients who underwent a CTT at Duke University Hospital from 2001 to 2016. Ten patients were excluded from the study owing to a history of MM, resulting in 1154 patients in the study. Five patients who developed MM after CTT were identified. EXPOSURES: Exposures included tacrolimus, prednisone, and mycophenolate mofetil. MAIN OUTCOMES AND MEASURES: The primary outcome measurement was the MM incidence. Secondary outcomes included time to diagnosis and survival. RESULTS: Five of 1154 patients who underwent a CTT (0.4%) developed biopsy-proven MM at a median follow-up time of 4.3 years after transplantation at a median age of 64.5 years (range, 31.0-74.0 years). Of the 1154 patients, 923 (80%) were men. Their mean (SD) age range was 63.8 years (27.2-68.2 years). Four patients (80%) presented with stage I disease while 1 (20%) presented with stage IV disease at a median time of 2.5 years (range, 0.1-5.3 years) after transplant compared with a median time of 6.2 years (range, 0.9-8.7 years) in Duke University's renal transplant population at a median follow-up time of 6.6 years. Two patients died after transplant, 1 owing to complications of the transplant and 1 owing to metastatic MM. CONCLUSIONS AND RELEVANCE: Representing one of the largest reported studies of patients with CTT developing MM, our findings suggest that the CTT population experiences an incidence of MM similar to that of other solid organ transplant recipients and with a median of 2.5 years from transplant to melanoma diagnosis. While the small scale of our study prevents far-reaching conclusions, further study is warranted to better understand the incidence, timing, and clinical ramifications of melanomagenesis in the CTT population.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Puza CJ, Cardones AR, Mosca PJ, et al. Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population. JAMA Dermatol. 2018. PMID: 29453871. doi:10.1001/jamadermatol.2018.0130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。